NAD+ Injectable
27
Vendors
81
Samples
6.2
Avg Score
| # | Vendor | Rating | Count | Avg | Min | Max | Most Recent |
|---|---|---|---|---|---|---|---|
| 1 | Homopeptide | A | 7 | 10.0 | 9.9 | 10.0 | 24 May 2026 |
| 2 | Tianjin Finder Chemical TFC | A | 4 | 10.0 | 9.9 | 10.0 | 16 Apr 2026 |
| 3 | Sangon Bio | A | 4 | 10.0 | 9.9 | 10.0 | 5 Jul 2026 |
| 4 | Shanghai ERP Biotechnology | A | 3 | 9.9 | 9.9 | 10.0 | 28 Mar 2026 |
| 5 | Wuhan Wansheng Bio (WWB) | A | 2 | 9.6 | 9.1 | 10.0 | 23 May 2026 |
| 6 | Shanghai Sigma Audley SSA | A | 3 | 9.0 | 7.9 | 10.0 | 24 May 2026 |
| 7 | Glbiochem (Shanghai) | A | 6 | 8.5 | 7.5 | 9.8 | 24 May 2026 |
| 8 | Qingdao Sigma Chemical QSC | A | 8 | 8.0 | 6.3 | 9.2 | 23 May 2026 |
| 9 | Nantong Guangyuan Chemical GYC | A | 2 | 7.8 | 6.7 | 8.8 | 21 May 2026 |
| 10 | Peptronix Bio PTB | X | 1 | 8.9 | 8.9 | 8.9 | 14 Jan 2025 |
| 11 | Xianhong Tong XHT Peptides | X | 1 | 7.7 | 7.7 | 7.7 | 2 Jul 2025 |
| 12 | HK Peptides | A | 11 | 7.1 | 5.3 | 9.9 | 20 May 2026 |
| 13 | Tianjin Ruiwang New Material Technology Co | A | 7 | 7.1 | 4.6 | 8.5 | 24 May 2026 |
| 14 | Xingruida XDR | B | 4 | 6.9 | 5.4 | 8.1 | 23 May 2026 |
| 15 | Zhejiang Yichenkang Biotechnology | B | 4 | 6.4 | 4.6 | 8.2 | 17 May 2026 |
| 16 | Regenerative Research | X | 1 | 6.4 | 6.4 | 6.4 | 8 Jul 2025 |
| 17 | Yabang Peptide | X | 1 | 6.3 | 6.3 | 6.3 | 27 Feb 2025 |
| 18 | Bio Pepz | X | 1 | 6.2 | 6.2 | 6.2 | 27 Feb 2025 |
| 19 | Royal Peptides | B | 3 | 6.1 | 4.0 | 8.3 | 24 May 2026 |
| 20 | Laicuinuo LCN | X | 1 | 6.1 | 6.1 | 6.1 | 25 Apr 2025 |
| 21 | Pharma Grade Peptides | X | 1 | 6.0 | 6.0 | 6.0 | 8 Jul 2025 |
| 22 | Shenzhen Jiechuang Trading | X | 1 | 4.2 | 4.2 | 4.2 | 3 Jul 2025 |
| 23 | Wolverine Peptides | X | 1 | 3.7 | 3.7 | 3.7 | 9 Jun 2025 |
| 24 | Peptide Gurus | X | 1 | 2.5 | 2.5 | 2.5 | 8 Jul 2025 |
| 25 | Hebei Chengtong Technology | X | 1 | 1.7 | 1.7 | 1.7 | 16 Mar 2025 |
| 26 | Advanced Technology and Industrial | X | 1 | 0.0 | 0.0 | 0.0 | 2 Apr 2025 |
| 27 | PepLab Solutions | X | 1 | 0.0 | 0.0 | 0.0 | 24 Apr 2025 |